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Introduction: A randomized trial has demonstrated that lung cancer
screening reduces mortality. Identifying participant and program
characteristics that influence the cost-effectiveness of screening will
help translate trial results into benefits at the population level.
Methods: Six U.S. cohorts (men and women aged 50, 60, or 70
years) were simulated in an existing patient-level lung cancer model.
Smoking histories reflected observed U.S. patterns. We simulated
lifetime histories of 500,000 identical individuals per cohort in each
scenario. Costs per quality-adjusted life-year gained ($/QALY) were
estimated for each program: computed tomography screening;
stand-alone smoking cessation therapies (4–30% 1-year abstinence);
and combined programs.
Results: Annual screening of current and former smokers aged 50 to
74 years costs between $126,000 and $169,000/QALY (minimum
20 pack-years of smoking) or $110,000 and $166,000/QALY (40
pack-year minimum), when compared with no screening and assum-
ing background quit rates. Screening was beneficial but had a higher
cost per QALY when the model included radiation-induced lung
cancers. If screen participation doubled background quit rates, the
cost of annual screening (at age 50 years, 20 pack-year minimum)
was below $75,000/QALY. If screen participation halved back-
ground quit rates, benefits from screening were nearly erased. If
screening had no effect on quit rates, annual screening costs more
but provided fewer QALYs than annual cessation therapies. Annual
combined screening/cessation therapy programs at age 50 years
costs $130,500 to $159,700/QALY, when compared with annual
stand-alone cessation.
Conclusions: The cost-effectiveness of computed tomography
screening will likely be strongly linked to achievable smoking
cessation rates. Trials and further modeling should explore the
consequences of relationships between smoking behaviors and
screen participation.
Key Words: Lung cancer, Screening, Cost-utility analysis, Micro-
simulation model.
(J Thorac Oncol. 2011;6: 1841–1848)
The National Lung Screening Trial (NLST) released resultsearlier than planned on demonstrating that screening with
computed tomography (CT) (when compared with screening
with chest x-ray) reduced lung cancer mortality by 20%.1,2 As
noted by NLST investigators,1 the mortality reduction ob-
served in the self-selected, volunteer population (n 53,456)
under controlled trial settings will not eliminate all uncertain-
ties surrounding the effectiveness or value of screening in the
general population.3 Modeling can complement randomized
trials by simulating screening in populations with character-
istics different than trial participants under different scenarios
and comparing screening with other lung cancer control
interventions.
Because of the strong causal link between smoking and
lung cancer, mortality reductions possible with screening will
depend in part on whether screen participation alters a smoker’s
likelihood of quitting. CT screening has been described as a
potential “teachable moment” for motivating continuing
smokers to quit.4–7 Alternatively, if no lung cancer is de-
tected, smokers could believe that they will not develop
cancer and have been given license to continue to smoke.
Which of these effects, if either, will be observed in the
NLST is not yet clear. European studies have reported that
trial participants have higher quit rates than the general
population but small or no differences in quit or relapse rates
between participants in the control and screened arms.8,9
For this analysis, we used an existing microsimulation
model that previously predicted mortality reductions between
15% (15 years of follow-up) and 28% (6 years of follow-up)
for five annual screens in smokers with 20 pack-years of
exposure,10 compared with 20% reduction (6 years of follow-
up) for three annual screens in smokers with 30 pack-years of
exposure as reported by the NLST.1 Our model simulated
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cohorts of individuals representative of the U.S. population
and not specifically the NLST cohort. Treatment costs and
measures of health-related quality of life (QOL), as well as
risks of secondary lung cancers due to radiation exposure
from CT examinations, were incorporated. The mortality
reduction reported from the NLST was not used as an input
or calibration endpoint for this analysis.
The purpose of our study was to estimate the cost-
effectiveness of CT screening for lung cancer in the U.S.
population and to identify characteristics of lung cancer
screening programs (i.e., screen frequency and adherence,
eligibility, follow-up program, effects on cessation, and
costs) with the largest influences on the cost-effectiveness of
screening. We compared smoking cessation therapies with
screening and with programs that combined smoking cessa-
tion and screening.
MATERIALS AND METHODS
This study used publicly available deidentified human
subject data and the single cohort Lung Cancer Policy
Model (LCPM), previously used to predict the long-term
effectiveness of screening10,11 (see Supplemental Digital
Content 1, http://links.lww.com/JTO/A134, which pro-
vides additional methods and model details, Supplemental
Digital Content 2, http://links.lww.com/JTO/A135, which
provides a schematic of the model, Supplemental Digital Con-
tent 3, http://links.lww.com/JTO/A136, which provides model
inputs specific to this analysis, Supplemental Digital Content 4,
http://links.lww.com/JTO/A137, which provides costs used for
this analysis, and www.cisnet.cancer.gov/profiles for details on
the LCPM, including references for model inputs, calibration
and validation, and prior applications).
The LCPM is a patient-level microsimulation model of
lung cancer development, progression, detection, treatment,
and survival. Lung cancer natural history parameters were
previously estimated by calibration against tumor registry
data on age-specific lung cancer incidence rates, distributions
of size, stage and cell types of incident lung cancers, and lung
cancer-specific survival. Lung cancers have varied progres-
sion rates and can be five major histologies. Model validation
included reproducing endpoints from two screening studies
(rates of positive screens, stage, and cell type distributions)
and two cohort studies (mortality).
The model simulates symptomatic, incidental, and (for
screening scenarios) screen detection of benign and malig-
nant pulmonary nodules. Sensitivity of screening CT exam-
inations is a function of the diameter and location (central
versus peripheral) of a pulmonary nodule. CT has a sensitiv-
ity of 0.63 for peripheral nodules of 1 mm in diameter, 0.77
for peripheral nodules of 4 mm in diameter, and 1.0 for
peripheral nodules of 8 mm in diameter or larger. CT was
assumed to have lower sensitivity for central nodules (75% of
that for peripheral nodules of the same size) to account for
obstruction by the aorta, etc. Pulmonary nodules (benign and
malignant) detected on imaging examinations are triaged by
size. In the base case, nodules less than 4 mm are not
followed, nodules 4 to 8 mm are followed by serial high-
resolution CT (at months 1, 3, 6, 9, 12, and 24), and nodules
8 mm are biopsied with bronchoscopy, fine-needle biopsy,
or video-assisted thoracoscopy. In sensitivity analyses, we
simulated fewer high-resolution CT examinations (4–6 mm
nodules were followed at months 9 and 24 and 6 to 8 mm at
months 6, 12, and 24).
Survival after diagnosis is modeled explicitly as a
function of treatment and underlying disease characteristics
(not using a stage shift as in previous studies12). Staging and
treatment of non-small cell lung cancer and small cell lung
cancer followed National Comprehensive Cancer Network
consensus guidelines in place in 2000. Invasive examinations
and surgical resection are associated with operative mortality
in the model.
Smoking histories (ages of starting and stopping smok-
ing and an average dose) representative of six cohorts of U.S.
white males and females aged 50, 60, and 70 years in 1990
were derived from survey data and used to generate six fixed
cohorts of 500,000 individuals.11,13 Competing mortality risks
were stratified by smoking status, age, and sex. No lung cancer
screening was recommended during the 1990s; thus, the no-
intervention scenario corresponds to observed incidence.
Smoking Cessation
Current smokers faced an annual background rate of
smoking cessation of 3%,14 uncorrelated with pack-years.
Except where noted, screen participation was uncorrelated
with the probability of cessation.
We investigated the effects of a smoking cessation
therapy consisting of bupropion and nicotine replacement
therapy prescribed to current smokers. Omitting the distinc-
tion between therapy uptake and efficacy, 1-year abstinence
rates evaluated were 4%, 8%, 16%, or 30% (versus 3%
background), reflecting estimates that vary widely depending
on the population and intervention.15–19 Unless offered ces-
sation therapy at the next program visit, individuals with
elevated cessation rates were assumed to revert to the back-
ground 3% after 1 year.
Benefits and Harms of Screening
In the model, features of the screening program (CT
sensitivity, frequency of screening examinations, and eligi-
bility for screening) are translated into estimates of the
effectiveness of screening. In other words, the effectiveness
of screening (i.e., the relative reduction in mortality) is a
model output, generated as a nonlinear function of the ben-
efits and harms of screening. Screening effectiveness cannot
be directly varied to identify thresholds for screening to be
cost-effective.
Screening leads to detection of asymptomatic, preva-
lent lung cancers, and benign pulmonary nodules. The pro-
portion of screening examinations with positive results (both
false positive [benign] and true positive [cancer]) varies with
the age of the cohort, the number of screens, and the defini-
tion of a positive test. On a baseline (prevalent) screen with
small (4 mm) nodules categorized as “not suspicious for
lung cancer,” the positivity rate is approximately 20%.13 The
model predicts that screening leads to an excess of lung
cancer cases; the magnitude of the excess varies with num-
bers of screens and length of follow-up.10,11 Harms from
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screening include operative mortality, costs of follow-up
examinations (for both cancer and ultimately benign nod-
ules), and an increased risk of subsequent lung cancers (with
all attendant costs and outcomes) arising from radiation
exposure from screening and follow-up CT examinations (see
Supplemental Digital Content 1, which provides details of
radiation risk component). No disutilities from screening-
related anxiety were considered.
Except where noted, all eligible individuals were assumed
to participate in screening. In a sensitivity analysis, 70% of
eligible individuals adhered to their screening schedule.
Except where noted, screening had no effect on the
probability of smoking cessation.8 The direction and magni-
tude of any independent effect of screening on smoking
cessation are unknown, so we postulated a wide range of
pessimistic to optimistic scenarios in sensitivity analyses:
each instance of screening participation could reduce (to
1.5%; pessimistic scenario) or increase (to 4% or 6%; opti-
mistic scenarios) an individual’s probability of quitting smok-
ing over the subsequent year.
Costs and QOL
Diagnosis, staging, and treatment costs were derived from
Medicare reimbursements. Costs of diagnostic tests (including
screening CTs) were estimated by 2006Medicare payments (per
CPT code in the Physician Fee Schedule). Details of treatment
costs by phase of care are available elsewhere.20 Surveillance,
Epidemiology and End Results-Medicare linked data were used
to create patient-level monthly costs, grouped into baseline
(prediagnosis), initial (30 days to 7 months after diagnosis),
continuing, and terminal (final month of life) phases of care and
stratified by stage, histology (non-small cell lung cancer versus
small cell lung cancer), and treatment (surgery, radiation, and
chemotherapy). The initial phase excluded the first 30 days
postdiagnosis, which encompassed costs of dissimilar staging
algorithms. Baseline (nonlung cancer) medical costs were esti-
mated as costs accrued in a 12-month period before presentation
with lung cancer (excluding 3 months immediately preceding
diagnosis to subtract costs of treating undiagnosed lung cancer).
This analysis used constant costs (averaged during 1992–2003,
in constant 2006$). We replaced continuing-phase treatment
costs with baseline costs for long-term (3 or 5 years) survivors
in a sensitivity analysis.
Patient-time costs for diagnostic tests and treatments
were estimated using age-specific wages of an average
worker in 2006 (U.S. Bureau of Labor Statistics). Caregiver
time (e.g., accompanying patient to chemotherapy) was as-
sumed equal to patient time for diagnostics, surveillance, and
initial phases of care and represented by the cost of hospice
care for the terminal phase. Costs of pharmaceuticals (e.g.,
antiemetics and smoking cessation therapies) were estimated
by average wholesale prices (Red Book, Thompson Reuters).
The cost of a smoking cessation intervention (see later)
was estimated at $300, based on a combination of 1 month of
24-hour nicotine transdermal patches (Watson labs, 7 or 14 mg;
$188) plus 30 days of 300 mg bupropion HCl (Watson labs, 150
mg tablets; $116). Separately, the cost of cessation was in-
creased sixfold to represent a longer treatment duration and/or
additional costs required to achieve the same cessation rates.
Baseline QOLweights for nonlung cancer states, stratified
by age and gender, were U.S.-specific standardized values de-
rived from survey participants’ self-reported health as measured
by the EQ-5D.21 To avoid a possible increase in health-related
QOL from treatment for lung cancer, we multiplied the baseline
weights by weights for lung cancer states. Studies of QOL in
patients with lung cancer provide cell type, stage, and treatment-
specific QOL scores derived from patients using a variety of
assessment instruments22–24 and transformed into utilities.22 In
the base case, patients undergoing resection (lobectomy) expe-
rienced a 3-month disutility and then a return to baseline.25
Analyses
Costs and quality-adjusted life-years (QALYs) were
discounted at 3% annually.26 Incremental cost-effectiveness
ratios were calculated for nondominated strategies in 2006
U.S. $/QALY.26 A strategy was dominated if it costs more
but provided fewer benefits than a comparator or if it had a
higher incremental cost-effectiveness ratio than a more effec-
tive strategy (weakly dominated).
Ratios were first calculated for CT screening versus no
intervention. For the base case and the scenarios that incorpo-
rated risks of radiation-induced lung cancer, individuals with
20 pack-years were eligible. Scenarios with more restrictive
eligibility or independent effects of screen participation on
cessation but no radiation risks were also evaluated.
Alternative program characteristics (CT sensitivity,
screening adherence, diagnostic test costs, operative mortality,
and follow-up of nodules 4 mm) and assumptions regarding
QOL (a return to baseline QOL at 1, 6, 12, or 24 months after
lobectomy or never27) were simulated in 50-year-old men.
Cessation alone and a combined cessation/screening
were simulated in 50-year olds. The combined program
consisted of screening CT for current and former smokers,
plus bupropion and nicotine replacement therapy prescribed
to current smokers at the screening examination.
Statistical Methods
We simulated lifetime histories of the six fixed cohorts of
500,000 individuals described earlier in each scenario. The
number of first-order trials is scalable, and second-order uncer-
tainty is not considered in these analyses. Thus, p values for
comparisons between strategies are uninformative and not re-
ported.
RESULTS
Per person screened (20 pack-years), the incremental
lifetime healthcare costs for a single screen (versus no screen)
varied from $1778 to $3637 and provided between 0.009 and
0.022 additional QALYs ($144,000–$207,000/QALY). Cor-
responding gains in undiscounted life-years ranged from
0.018 to 0.045 (7–16 days). One-time screening provided
reductions in lung cancer-specific mortality of between 5.02
and 7.52% compared with no screening.
In all cohorts, single screening was excluded by weak
dominance. Compared with no screening, annual screening of
persons with at least 20 pack-years of smoking history re-
duced lung cancer-specific mortality by 17.98 to 25.16% at
10 years at a cost of $126,000 to $169,000/QALY (Table 1).
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Including risks of radiation-induced lung cancer yielded
smaller mortality reductions and higher costs ($139,000–
$203,000/QALY, Table 1, follow-up CT dose of 58 mGy).
Alternate estimates for organ doses for follow-up CTs (both
10 mGy and 90 mGy were used) yielded a range of $133,000
to $247,000/QALY (not shown). Follow-up algorithms with
fewer CT examinations yielded ranges of $121,000 to
$160,000/QALY without radiation risks and $127,000 to
$160,000/QALY with radiation risks (Table 1).
Restricting screening to individuals with 40 pack-
years, current smokers, or current smokers and recent quitters
yielded ratios from $110,000 to $166,000/QALY (Table 2).
Single screens were weakly dominated.
In cohorts of 50-year olds, if screen participation itself
was associated with a doubling (to 6%) of the background
cessation rate, annual screening (perfect adherence) was as-
sociated with a cost (versus no screening) of $73,000/QALY
(men) and $40,000/QALY (women), whereas a 33% increase
(to 4%) of background cessation resulted in cost-effective-
ness ratios of $105,000/QALY (men) and $97,000/QALY
(women). In the pessimistic scenario in which screen partic-
ipation was associated with a 50% reduction (to 1.5%) in
cessation, the cost-effectiveness ratios were $880,000/QALY
(men) and more than $1 million/QALY (women; Table 3).
Treatment costs that return to baseline at 36 or 60
months after resection (versus base case 100 months) yielded
ratios of $134,000/QALY or $135,000/QALY (women) and
$145,000/QALY or $146,000/QALY (men; Table 3).
In a cohort of 50-year-old men, imperfect (70%) ad-
herence to annual screening was associated with a cost
(versus no screening) of $180,000/QALY (Table 4). Perfect
sensitivity of CT for peripheral pulmonary nodules yielded a
ratio of $141,000/QALY (Table 4), comparable with the base
case: most of the additional nodules detected were less than
4 mm and therefore not followed. Neither following nodules
less than 4 mm nor a reduction in the cost of screening CT
was associated with a ratio of less than $100,000/QALY.
Reductions in operative mortality for lobectomy and invasive
staging examinations reduced the ratio to $141,000/QALY.
Prolonged delays before a return to baseline health after
resection yielded greater costs per QALY.
One-time smoking cessation therapy costing $300 costs
between $11,400/QALY (30% cessation, men) and $69,300/
QALY (4% cessation, women), compared with no interven-
tion (Table 5). Annual smoking cessation therapy programs
offered additional benefits at costs from $12,500 to $69,400/
QALY. An annual combination strategy yielded more bene-
fits than annual cessation therapy alone but at an incremental
TABLE 1. Annual CT Screening (20 Pack-Year Smoking History) vs. No Intervention
Cohort
Sex
Cohort
Age (Yr)
Screen
Frequency/
Age Range (Yr)
% of
Cohort
Screened
Risk of
Radiation-
Induced
Lung Cancer
Fewer
Follow-Up CT
Examinations
Incremental
Cost-Effectiveness
Ratio ($/QALY)
Mortality
Reduction (%)
Versus No
Intervention,
(10-Yr Follow-Up)
Mortality
Reduction (%)
Versus No
Intervention,
(15-Yr Follow-Up)
Males 50 Annual/50–70 69   149,000 25.16 28.69
  158,000 25.06 28.08
  147,000 23.15 24.80
  150,000 23.14 24.69
60 Annual/60–74 72   135,000 25.06 27.66
  139,000 24.96 27.18
  129,000 23.01 23.80
  130,000 22.99 23.71
70 Annual/70–74 70   169,000 20.94 16.21
  172,000 20.85 15.92
  160,000 19.45 14.81
  160,000 19.43 14.77
Females 50 Annual/50–70 40   137,000 19.48 22.37
  203,000 19.18 19.63
  135,000 18.09 19.44
  152,000 18.03 19.00
60 Annual/60–74 47   126,000 23.07 25.21
  151,000 22.80 22.87
  121,000 21.15 21.60
  127,000 21.08 21.16
70 Annual/70–74 39   159,000 17.98 13.26
  172,000 17.76 12.00
  153,000 16.10 11.61
  156,000 16.11 11.35
Scenarios that included () risks of radiation-induced lung cancer assumed 3.8–3.9 mGy (screening CT) and 58 mGy (follow-up CT) organ doses and a 10-yr lag between
exposure and incidence. See text for details of scenarios that modeled () less-intensive follow-up. Costs and QALYs discounted at 3% annually.
CT, computed tomography; QALY, quality-adjusted life-year.
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cost from $130,500 to $159,700/QALY (see Supplemental
Digital Content 5, http://links.lww.com/JTO/A138, which
is a figure legend for Supplemental Digital Content 6,
http://links.lww.com/JTO/A139, which is a plot of costs
versus effects).
Cessation therapy costing $1800 and yielding 4% ab-
stinence was weakly dominated by annual screening in 50-
year olds. Results for abstinence rates of 8% or higher
followed a pattern similar to the $300 cessation therapy:
ratios less than $60,400/QALY for annual cessation therapy
and more than $100,000/QALY for annual combination pro-
grams (not shown).
DISCUSSION
The NLST recently provided evidence that individuals
randomized to three annual CT screens had 20% lower lung
cancer-specific mortality than individuals randomized to
TABLE 2. Annual CT Screening with Varying Eligibility vs. No Intervention
Eligibility Cohort Sex
Cohort Age
(Yr)
% of Cohort
Screened
$/QALY Compared
with No Intervention
Current and former heavy smokers
(minimum PY  40)
Male 50 29 $126,000
60 60 $132,000
70 58 $166,000
Female 50 1 n/r
60 15 $110,000
70 14 $142,000
Current and former smokers who
quit 10 yr ago (minimum PY  20)
Male 50 31 $126,000
60 25 $122,000
70 16 $147,000
Female 50 27 $127,000
60 22 $112,000
70 14 $142,000
Current heavy smokers (minimum
PY  40)
Male 50 29 $130,000
60 23 $123,000
70 16 $149,000
Female 50 1 n/r
60 15 $112,000
70 13 $145,000
PY, pack-years; n/r, not reported because1% of simulated women aged 50 years had accumulated40 PY; CT, computed tomography;
QALY, quality-adjusted life-year.
TABLE 3. Annual CT Screening vs. No Intervention:
Sensitivity Analyses in Cohorts of Men and Women Aged 50 Yr
Scenario
$/QALY Compared
with No Intervention,
Men Age 50 Yr
$/QALY Compared
with No Intervention,
Women Age 50 Yr
Base casea $149,000 $137,000
Screen participation
increases cessation
rate to 6%
$73,000 $40,000
Screen participation
increases cessation
rate to 4%
$105,000 $97,000
Screen participation
cuts cessation rate
in half to 1.5%
$880,000 $1,034,000
Duration of increased
treatment costs
after resection
3 yr $145,000 $134,000
5 yr $146,000 $135,000
a Base case assumed 3% annual background cessation rate, perfect adherence, and
8-yr continuing treatment costs after resection.
CT, computed tomography; QALY, quality-adjusted life-year.
TABLE 4. Annual CT Screening vs. No Intervention:
Sensitivity Analyses in Cohorts of Men Aged 50 Yr
Scenario
$/QALY Compared
with No Intervention
Base casea $149,000
70% adherence to screening $180,000
CT sensitivity  100% $141,000
Less-costly helical CT ($188, HOPPS) $120,000
Follow-up nodules 4 mm $148,000
Lower operative mortality (3%, lobectomy;
0.1% mediastinoscopy; 0.2% VATS)
$141,000
Delay before return to baseline health after
resection
1 mo $147,000
6 mo $150,000
12 mo $154,000
24 mo $161,000
No recovery $209,000
a Base case values: perfect adherence; CT sensitivity based on diameter; screening
CT cost of $283 based on Physician Fee Schedule; no follow-up of nodules 4 mm;
operative mortality 4% (lobectomy), 0.3% (mediastinoscopy), and 0.5% (VATS); and 3
mo recovery after resection.
HOPPS, Hospital Outpatient Prospective Payment System; VATS, video-assisted
thoracoscopy; CT, computed tomography; QALY, quality-adjusted life-year.
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three annual chest x-ray screens.1 The NELSON trial (n 
15,822) is powered to show a mortality reduction of 25%
from CT screening, compared with usual care.28 It was not
possible to simulate these trials or to calibrate to the NLST
results, because we did not have individual level demograph-
ics and smoking histories (pack-years decomposed into dose
and duration over time) necessary to predict lung cancer
risks. We, therefore, simulated cohorts of individuals repre-
sentative of the U.S. population. Further, we did not include
a module for chest x-ray screening and could not simulate the
NLSTs follow-up patterns for individuals with millimeter-
sized nodules (the study design did not specify a protocol).
Our analysis, completed before release of the NLST results,
predicted a range of 17.76 to 25.16% reduction in lung
cancer-specific mortality at 10 years, depending on the num-
ber of screens (4–10), the cohort, and whether radiation risks
are included (Table 1), compared with no intervention. Other
modeling studies of the effectiveness of CT screening com-
pleted before the NLST predicted benefits ranging from no
benefit29 to reductions in lung cancer-specific mortality of 8.0
to 45.6%, depending on model assumptions and screening
program characteristics (e.g., eligibility criteria, screening
modality and frequency, patient management, and length of
follow-up).10,12,30–34
We found that unless screen participation increases
smoking cessation, lung cancer screening was considerably
more expensive than other U.S. screening programs. Colo-
rectal cancer screening—widely viewed to be cost-effec-
tive—has cost-effectiveness ratios (versus no screening) in
the range of $13,000 to $32,000/LY (2006$).35 Breast cancer
screening of women aged 40 years or older with mammog-
raphy has a cost-effectiveness ratio compared with no screen-
ing of $47,700/QALY (2006$).36
We predicted low costs per QALY for cessation ther-
apy, consistent with estimates that range from cost saving to
$17,000/QALY (2006$).37–39 Much of the gain in life expec-
tancy after cessation is due to decreases in deaths from causes
other than lung cancer.40
Our base case estimates of $126,000 to $169,000/
QALY for annual screening of 50–70-year-old ever smokers
is comparable with a prior estimate of $143,000/QALY
(2006$) for annual CT screening of current smokers.12 Our
microsimulation approach includes a natural history model
calibrated to tumor registry data rather than a stage shift as
the mechanism for screening effectiveness, so did not require
estimates of screening biases as inputs. Our approach simu-
lates symptom-related and incidental detection of lung can-
cers in addition to screen detection and permitted evaluation
of strategies using cessation therapy and programs that used
different follow-up algorithms and eligibility. We showed that
the influences of eligibility, screening frequency, adherence,
frequency of follow-up CT examinations, and accumulated ra-
diation risks on cost-effectiveness were smaller in magnitude
than influences of cessation. Our model suggests that results
from screening trials should be interpreted with consideration
given to the specifics of any cessation component.
Our “no-intervention” scenarios were fit to observed
incidence rates and used contemporaneous inputs but are
historical and omit advances in staging and targeted thera-
pies. Our assumption that patients undergo guideline care was
common to all scenarios but overestimates the percentage of
patients who undergo lobectomy. Our results may thus over-
estimate the gain in QALYs attributable to screening. We
allow for nonoperative candidates (7.7%), but an additional
16 to 20% (depending on age) of early-stage patients in
Surveillance, Epidemiology and End Results do not undergo
surgery for unspecified reasons. Our analysis was limited to
whites due to insufficient individual level data in other
populations on smoking histories and cancer outcomes nec-
essary for model development.
We assumed a societal perspective, which dictated
inclusion of all costs without regard to who pays them. We
used Medicare fee schedules, which were in part designed to
approximate the resource use costs of all medical interven-
tions, including the initial screening examination, which is
not typically reimbursed.26 Use of health-related QOL in-
dexes other than the EQ-5D for the general population would
have yielded different QALY totals, but because trends by
age are similar across standard indexes,41 the incremental
change in QALYs and therefore costs per QALY between
scenarios would be similar to those we estimated.
Imperfect uptake of cessation therapies would likely
translate to abstinence rates closer to the lower end (4%) of
the range we evaluated than the maximum (30%). We did not
vary screening’s effect on cessation according to the test
result and did not consider perceptions of lung cancer risk,
which may influence participation and cessation.7,42 Our
predicted mortality reduction from annual screening in the
absence of radiation-induced lung cancers (16% in all
cohorts) exceeded a threshold (1–4%) postulated to outweigh
risks of radiation-induced lung cancers (50–52-year-old male
current smokers).43 When risks of radiation-induced lung
TABLE 5. Screening or Cessation Alone vs. Combination (Cessation Therapy Offered at Screening of Both Current and
Former Smokers 20 Pack-Years), in Cohorts of 50-Yr Olds
Strategies
Men: 1-Yr Abstinence with
Cessation Therapy
Women: 1-Yr Abstinence with
Cessation Therapy
4% 8% 16%a 30% 4% 8% 16% 30%
Cessation alone, single $49,100 $17,700 $12,900 $11,400 $69,300 $20,800 $14,400 $12,400
Cessation alone, annual $57,600 $20,800 $14,900 $12,500 $69,400 $23,900 $16,600 $13,700
Combination, annual $144,500 $153,900 $158,800 $159,700 $130,500 $139,300 $145,800 $146,800
a Shown in Figure 1 (Supplemental Digital Content 6, http://links.lww.com/JTO/A139). Table based on $300 cessation therapy and 3% baseline annual cessation in
no-intervention and screening-alone scenarios (screening alone was dominated).
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cancers were included in the model, estimated mortality
reductions at 15 years were within 1% (on an absolute scale)
of the base case estimates in male cohorts and within 3% in
female cohorts. Reducing the frequency of follow-up CT
examinations reduced the magnitude of the effect of radiation
risk on 15-year mortality reductions (within 1% in all co-
horts) from screening but did not alter the conclusions: the
risk of radiation-induced lung cancers was outweighed by the
reduction in deaths from lung cancer attributed to screening.
Fewer follow-up CT examinations not only reduced radiation
risks but also delayed detection of some small, growing
cancers: mortality reductions were lower compared with the
base case, and the cost for all six cohorts remained more than
$120,000/QALY.
Changes to several model inputs could result in higher
costs per QALY than estimated in this study: an increased
cost of the screening CT examination or other treatments (for
instance, to reflect retail prices rather than opportunity costs
and the societal perspective we adopted); addition of positron
emission tomography-CT in the staging algorithm (although
costs of positron emission tomography-CT would be offset by
some reductions in excisional biopsies); and addition of
targeted therapies for lung cancer such as erlotinib (although
the cost per QALY would offset by increased survival for
patients with sensitizing mutations).
In conclusion, results from a microsimulation model
suggest that the cost-effectiveness of CT screening programs
will be strongly influenced by smoking cessation rates among
screen participants. The specific eligibility criteria will be
more influential on the cost-effectiveness of screening than
other program characteristics such as the screening test cost
or radiation risks. Unless screen participation increases the
probability of cessation, screening with helical CT may cost
more than $100,000/QALY compared with no intervention
and be more expensive and provide fewer QALYs than an
annual cessation intervention. A combined screening/cessa-
tion program would offer benefits to both current and former
smokers but would cost more than $100,000/QALY. Under-
standing behaviors surrounding smoking and screen partici-
pation6,7 will be critical for translating trial results into
population benefits.
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